INNOCARE PHARMA LTD risk profile
33 Normal where most of the sector sits
Measured 1 September 2026 from 33C's filed statements. Recomputed nightly.
33 (Normal), driven by Cash conversion at 72, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 56 | Elevated | Worsening | Drawdown from the 52-week high — 27.4% |
| Operating pressure | 0 | Contained | Easing | Costs outgrowing revenue — -112.9 percentage points |
| Cash conversion | 72 | Stretched | Easing | Cash conversion — 0.13x |
| Leverage and coverage | 4 | Contained | Easing | Interest cover — 15.30x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for INNOCARE PHARMA LTD